Reducing Anxiety and Dyspnea via Device-guided Breathing

Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

IMscin001 Part 2: A Randomised Phase 3, Open-label, Multicentre Study Examining the Pharmacokinetics, Efficacy, Immunogenicity, and Safety of Atezolizumab Subcutaneous versus Intravenous in Previously Treated Locally Advanced or Metastatic NSCLC

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

Reducing Anxiety and Dyspnea via Device-guided Breathing

header-info

Apr, 13, 2023

In the WF-01213 study, lung cancer survivors identified through the NCI Community Oncology Research Program were randomized to undergo either 12 weeks of device-guided breathing intervention or usual breathing control device intervention in an attempt to improve self-reported anxiety and dyspnea. Researchers reported decreased anxiety and dyspnea in all groups, but found that making time to use the device was most difficult for patients.

Access the full article to read more here.